Safety of the nonselective NSAID nabumetone : focus on gastrointestinal tolerability.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Drug Safety

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 18484783
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Microcomputer-Assisted Study of Nabumetone and Slow Release Diclofenac in Osteoarthritis

  2012cited by this paper
• An Overview of the Long Term Safety Experience of Nabumetone

  2012cited by this paper
• Nabumetone

  2012cited by this paper
• Nonsteroidal Anti-Inflammatory Drugs and Heart Failure

  2012cited by this paper
• Lumiracoxib in the management of osteoarthritis and acute pain

  2007cited by this paper
• Nonsteroidal anti-inflammatory drug-induced hepatotoxicity.

  2007cited by this paper
• NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland.

  2006cited by this paper
• Meta-analysis: cardiovascular events associated with nonsteroidal anti-inflammatory drugs.

  2006cited by this paper
• Systematic review: the lower gastrointestinal adverse effects of non‐steroidal anti‐inflammatory drugs

  2006cited by this paper
• Treatment of Patients With Osteoarthritis With Rofecoxib Compared With Nabumetone

  2006cited by this paper
• Intestinal tract injury by drugs: Importance of metabolite delivery by yellow bile road.

  2006cited by this paper
• Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials

  2006cited by this paper
• NSAID injury to the gastrointestinal tract: evidence that NSAIDs interact with phospholipids to weaken the hydrophobic surface barrier and induce the formation of unstable pores in membranes

  2006cited by this paper
• Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs.

  2006cited by this paper
• Assessment and prevention of gastrointestinal toxicity of non‐steroidal anti‐inflammatory drugs

  2006cited by this paper
• GI Risk and Risk Factors of NSAIDs

  2006cited by this paper
• Use of Non-Aspirin Nonsteroidal Antiinflammatory Drugs and the Risk of Cardiovascular Events

  2006cited by this paper
• Do Selective Cyclo-Oxygenase-2 Inhibitors Have a Future?

  2005cited by this paper
• Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population.

  2005cited by this paper
• Risk of hospitalization with peptic ulcer disease or gastrointestinal hemorrhage associated with nabumetone, Arthrotec, diclofenac, and naproxen in a population based cohort study.

  2005cited by this paper
• Nonsteroidal anti-inflammatory drugs and hepatic toxicity: a systematic review of randomized controlled trials in arthritis patients.

  2005cited by this paper
• Balancing the gastrointestinal benefits and risks of nonselective NSAIDs

  2005cited by this paper
• Renal effects of non-steroidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors.

  2005cited by this paper
• Current Use of Nonsteroidal Antiinflammatory Drugs and the Risk of Acute Myocardial Infarction

  2005cited by this paper
• Nonsteroidal antiinflammatory drugs and the small intestine

  2005cited by this paper
• Efficacy and Safety of Rofecoxib 12.5 mg Versus Nabumetone 1,000 mg in Patients with Osteoarthritis of the Knee: A Randomized Controlled Trial

  2004cited by this paper
• The hepatotoxicity of non‐steroidal anti‐inflammatory drugs

  2004cited by this paper
• The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis*

  2004cited by this paper
• A population based historical cohort study of the mortality associated with nabumetone, Arthrotec, diclofenac, and naproxen.

  2004cited by this paper
• Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach

  2004cited by this paper
• Spontaneous Reports of Hypertension Leading to Hospitalisation in Association with Rofecoxib, Celecoxib, Nabumetone and Oxaprozin

  2004cited by this paper
• Adverse effects of conventional non‐steroidal anti‐inflammatory drugs on the upper gastrointestinal tract

  2003cited by this paper
• Nonsteroidal antiinflammatory drugs and a selective cyclooxygenase 2 inhibitor uncouple mitochondria in intact cells.

  2003cited by this paper
• Effects of nabumetone, celecoxib, and ibuprofen on blood pressure control in hypertensive patients on angiotensin converting enzyme inhibitors.

  2003cited by this paper
• An open label study to establish dosing recommendations for nabumetone in juvenile rheumatoid arthritis.

  2003cited by this paper
• COX-2 selective inhibitors: analysis of the renal effects

  2002cited by this paper
• The different patterns of blood pressure elevation by rofecoxib and nabumetone

  2002cited by this paper
• Where is the evidence that cyclooxygenase inhibition is the primary cause of nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal injury? Topical injury revisited.

  2001cited by this paper
• A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis

  2001cited by this paper
• Treatment of Elderly Patients with Nabumetone or Diclofenac: Gastrointestinal Safety Profile

  2001cited by this paper
• The coxibs, selective inhibitors of cyclooxygenase-2.

  2001cited by this paper
• Randomized trial of low‐dose misoprostol and naproxen vs. nabumetone to prevent recurrent upper gastrointestinal haemorrhage in users of non‐steroidal anti‐inflammatory drugs

  2001cited by this paper
• Cyclooxygenase selectivity of non-steroid anti-inflammatory drugs in humans: ex vivo evaluation.

  2001cited by this paper
• Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

  2000cited by this paper
• Tolerability and efficacy of nabumetone and naproxen in the treatment of rheumatoid arthritis.

  2000cited by this paper
• Safety and efficacy of nabumetone in osteoarthritis: emphasis on gastrointestinal safety

  2000cited by this paper
• Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.

  1999cited by this paper
• Rationalizing cyclooxygenase (COX) inhibition for maximal efficacy and minimal adverse events.

  1999cited by this paper
• Profile and mechanisms of gastrointestinal and other side effects of nonsteroidal anti-inflammatory drugs (NSAIDs).

  1999cited by this paper
• Comparison of the upper gastrointestinal safety of Arthrotec 75 and nabumetone in osteoarthritis patients at high risk for developing nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers.

  1999cited by this paper
• Nabumetone Induces Less Gastrointestinal Mucosal Changes Than Diclofenac Retard

  1999cited by this paper
• Interaction of indomethacin and naproxen with gastric surface-active phospholipids: a possible mechanism for the gastric toxicity of nonsteroidal anti-inflammatory drugs (NSAIDs).

  1999cited by this paper
• Epidemiology of NSAID induced gastrointestinal complications.

  1999cited by this paper
• Gastrointestinal safety profile of nabumetone: a meta-analysis.

  1999cited by this paper
• Intestinal permeability and inflammation in patients on NSAIDs

  1998cited by this paper
• Clinical Pharmacokinetics of Nabumetone

  1997cited by this paper
• Mitochondrial damage: a possible mechanism of the “topical” phase of NSAID induced injury to the rat intestine

  1997cited by this paper
• Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study

  1997cited by this paper
• Value of epidemiologic studies in determining the true incidence of adverse events. The nonsteroidal anti-inflammatory drug story.

  1997cited by this paper
• A double-masked comparison of Naprelan and nabumetone in osteoarthritis of the knee. Naprelan Study Group.

  1997cited by this paper
• Nonsteroidal anti-inflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation.

  1997cited by this paper
• Nonsteroidal antiinflammatory drugs and uncoupling of mitochondrial oxidative phosphorylation.

  1996cited by this paper
• Human whole blood assays for inhibition of prostaglandin G/H synthases-1 and-2 using A23187 and lipopolysaccharide stimulation of thromboxane B2 production

  1996cited by this paper
• Early pathogenic events in NSAID-induced gastrointestinal damage.

  1996cited by this paper
• A multicenter study of nabumetone and diclofenac SR in patients with osteoarthritis.

  1995cited by this paper
• Misoprostol Reduces Serious Gastrointestinal Complications in Patients with Rheumatoid Arthritis Receiving Nonsteroidal Anti-Inflammatory Drugs

  1995cited by this paper
• Gastroduodenal tolerability of nabumetone versus naproxen in the treatment of rheumatic patients.

  1995cited by this paper
• A longterm endoscopic evaluation of patients with arthritis treated with nabumetone vs naproxen.

  1994cited by this paper
• Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases.

  1994cited by this paper
• Nabumetone in elderly patients with osteoarthritis: economic benefits versus ibuprofen alone or ibuprofen plus misoprostol.

  1994cited by this paper
• A decision analysis model in the evaluation of NSAIDs in a managed care setting: a case study.

  1994cited by this paper
• Efficacy of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis.

  1993cited by this paper
• Efficacy and safety of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in the elderly.

  1993cited by this paper
• A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosa.

  1993cited by this paper
• Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs.

  1993cited by this paper
• Safety experience with nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis.

  1993cited by this paper
• Lack of enterohepatic circulation of the active metabolite of nabumetone in humans.

  1992cited by this paper
• Antiinflammatory and gastrointestinal effects of nabumetone or its active metabolite, 6-methoxy-2-naphthylacetic acid (6MNA)

  1992cited by this paper
• Worldwide safety experience with nabumetone.

  1992cited by this paper
• Nabumetone compared with indomethacin in the treatment of osteoarthritis in general practice.

  1992cited by this paper
• The unique pharmacologic profile of nabumetone.

  1992cited by this paper
• Nabumetone compared with naproxen in the treatment of rheumatoid arthritis: a multicenter, double blind, randomized, parallel group trial in hospital outpatients.

  1992cited by this paper
• Importance of local versus systemic effects of non-steroidal anti-inflammatory drugs in increasing small intestinal permeability in man.

  1991cited by this paper
• The effect of nabumetone and its principal active metabolite on in vitro human gastric mucosal prostanoid synthesis and platelet function.

  1990cited by this paper
• Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage.

  1989cited by this paper
• Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial.

  1988cited by this paper
• Safety evaluation of nabumetone in United States clinical trials.

  1987cited by this paper
• Gastric ulcer formation and cyclo-oxygenase inhibition in cat antrum follows parenteral administration of aspirin but not salicylate.

  1985cited by this paper
• Relationship of gastric mucosal damage induced in pigs by antiinflammatory drugs to their effects on prostaglandin production

  1982cited by this paper
• Gastric mucus and bicarbonate secretion in relation to mucosal protection.

  1981cited by this paper

• Core-shell engineered Col/Cs@ECM microspheres for macrophage-targeted intracellular drug release in RA therapy

  2025cites this paper
• Langmuir Monolayer Studies of Phosphatidylcholine Membranes with Naproxen on the Polysaccharide Subphase

  2025cites this paper
• Biopharmaceutical Characterization and Stability of Nabumetone–Cyclodextrins Complexes Prepared by Grinding

  2024cites this paper
• Prodrug-based nanomedicines for rheumatoid arthritis

  2024cites this paper
• Nabumetone and flufenamic acid pose a serious risk to aquatic plants: A study with Chlamydomonas reinhardtii as a model organism.

  2023cites this paper
• EFFECT OF NABUMETONE ON CELLULAR IMMUNE RESPONSES IN MICE

  2020cites this paper
• The Association between Absence of Abdominal Pain and Mortality in Lower Intestinal Perforation in Patients with Autoimmune Rheumatic Diseases

  2019cites this paper
• Prevention of Renal Complications Induced by Non- Steroidal Anti-Inflammatory Drugs.

  2016cites this paper
• Evaluation of anti-inflammatory activity of selected medicinal plants used in Indian traditional medication system in vitro as well as in vivo

  2015cites this paper
• Impact of a stepwise protocol for treating pain on pain intensity in nursing home patients with dementia: A cluster randomized trial

  2014cites this paper
• Mirabegron : A Novel Treatment for Overactive Bladder

  2013cites this paper
• Medicinal chemistry of amine prodrugs

  2013cites this paper
• Increased Incidence and Impact of Upper and Lower Gastrointestinal Events in Patients with Rheumatoid Arthritis in Olmsted County, Minnesota: A Longitudinal Population-based Study

  2012cites this paper
• The membrane-activity of Ibuprofen, Diclofenac, and Naproxen: a physico-chemical study with lecithin phospholipids.

  2009cites this paper
• Single dose oral nabumetone for acute postoperative pain in adults.

  2009cites this paper
• Current awareness: Pharmacoepidemiology and drug safety

  2008cites this paper